L. Pare Brunet - Breast Cancer Research Group, SOLTI

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 10 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

12P Updated findings from the first prospective HER2DX clinical decision impact study on early-stage HER2-positive (HER2+) breast cancer (BC)

O. Martínez-Sáez, M. Marin, E. Hernández-Illán, A.I. Martinez-Puchol, P. Jares, J.A. Puig-Butille, E. Sanfeliu Torres, M.J. Vidal Losada, B. Adamo, T. Pascual, F. Schettini, B. Conte,

ESMO Open (2024)

引用0浏览0引用

8P Evaluating HER2DX pCR-Score and MRI response in predicting pathologic complete response (pCR) to anti-HER2 neoadjuvant chemotherapy (CT) in early-stage HER2-positive (HER2+) breast cancer (BC)

T. Pascual, O. Martínez-Sáez,L. Pare Brunet,G. Villacampa Javierre, A. Vivancos, X. Bargalló, S. Ganau, B. Úbeda, C. Sitges, M.J. Vidal Losada, B. Adamo, R. Gomez-Bravo,

ESMO Open (2024)

引用0浏览0引用

13P HER2DX ERBB2 mRNA score in first-line metastatic HER2-positive (HER2+) breast cancer (BC): Implications for treatment stratification

R. Sanchez Bayona, O. Martínez-Sáez, D.R. Romero,E. Segui Solis, E. Carcelero, P. Tolosa Ortega, J. Soberino García, M. Alva Bianchi, T. Pascual, A.M. Gaspar,G. Villacampa Javierre, W. Buckingham,

ESMO Open (2024)

引用0浏览0引用

74P Assessing the implementation of the HER2DX genomic test in a real-world setting for HER2-positive breast cancer

J.M. Cejalvo, J. Soberino, E.M. Ciruelos, J. Cortés, D. Generali, A.I. Martinez-Puchol, K. Amillano,S. Morales Murillo, S. Escrivá-De-Romaní,L. García Estevez, L. Bernet, J.A. Puig-Butille,

ESMO Open (2024)

引用0浏览0引用

49P A ctDNA tool for identifying ESR1-mutated biology in ESR1-non-mutated hormone receptor-positive (HR+) metastatic breast cancer (MBC)

I. Garcia Fructuoso, O. Martínez-Sáez, F. Pardo, M.D.R. Vega León, J. Matito,L. Pare Brunet, O. Castillo,G. Villacampa Javierre, P. Galván, J. Odegaard, P. Villagrasa Gonzalez, J. Parker,

ESMO Open (2024)

引用0浏览0引用

14P Assessing the predictive value of HER2DX pCR-score for pathologic complete response (pCR) in early-stage HER2-positive (HER2+) breast cancer (BC) under real-world conditions

O. Martínez-Sáez, M. Marin,L. Pare Brunet,G. Villacampa Javierre, A. Vivancos, M.J. Vidal Losada, B. Adamo,R. Gómez Bravo, I. Garcia Fructuoso, T. Pascual, N. Chic, P.R. Rivera,

ESMO Open (2024)

引用0浏览0引用

LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial